LEARN FROM THE EXPERTS!

Advances in Predictive Biomarkers for Immune Checkpoint Inhibitors in Lung Cancer: Why, Who, and How

Wednesday, November 6, 2019
6:30 PM - 7:00 PM  Registration and Dinner
7:00 PM - 8:30 PM  Symposium

Hilton Baltimore Inner Harbor
Holiday Ballroom 4-5
Baltimore, Maryland

A simulcast is available for AMP attendees who cannot make it to the live event or colleagues not able to attend the conference.

PROGRAM DIRECTOR
Hossein Borghaei, MS, DO
Fox Chase Cancer Center
Philadelphia, Pennsylvania

FACULTY
Sanjay Mukhopadhyay, MD
Cleveland Clinic
Cleveland, Ohio

Joshua Bauml, MD
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

CLINICAL CARE OPTIONS®

Supported by educational grants from AstraZeneca, Bristol-Myers Squibb, Genentech, and Merck Sharp & Dohme Corp.
On-site registration available or go to: www.clinicaloptions.com/Baltimore2019LungIO

Advances in Predictive Biomarkers for Immune Checkpoint Inhibitors in Lung Cancer:
Why, Who, and How

Wednesday, November 6, 2019
6:30 PM - 7:00 PM  Registration and Dinner
7:00 PM - 8:30 PM  Symposium

Hilton Baltimore Inner Harbor
Holiday Ballroom 4-5
Baltimore, Maryland

PROGRAM OVERVIEW
Join us for this engaging, CME/MOC-certified symposium at the 2019 AMP Meeting in Baltimore, Maryland, where our panel of both medical oncology and pathology experts will discuss optimal use of immunotherapy biomarkers in the treatment of patients with lung cancer.

AGENDA
6:30 PM  Registration and Dinner
7:00 PM  Program Overview
Hossein Borghaei, MS, DO
7:05 PM  The How: Current Predictors of Response to Immune Checkpoint Inhibitors
Sanjay Mukhopadhyay, MD
7:30 PM  The Why and Who: Overview of Immune Checkpoint Blockade in Lung Cancer
Joshua Bauml, MD
7:55 PM  The Future: Opportunities for Predictive Biomarkers in Cancer Immunotherapy
Hossein Borghaei, MS, DO
8:20 PM  Panel Discussion and Audience Question and Answer Session

GOAL
The goal of this activity is to improve participants’ knowledge of and competence in assessing biomarkers to guide the use of immune checkpoint inhibitors in the treatment of patients with lung cancer.

TARGET AUDIENCE
This program is intended for pathologists and other healthcare providers who treat and manage patients with lung cancer.

LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:
- Evaluate the clinical utility of predictive biomarkers for immune checkpoint inhibitor response in lung cancer by line of therapy, available therapeutic alternatives, and health economic considerations
- Compare and contrast the different methodologies and assays for identifying biomarkers of response to immune checkpoint inhibitors in different lung cancer histologies and treatment settings
- Implement best practices for biomarker testing/interpretation of results to guide treatment selection in different lung cancer histologies and treatment settings
- Summarize ongoing research regarding the utility of biomarkers, PD-L1, MSI/MMR, tumor mutational burden, DNA damage repair, T-cell functional state, composite biomarkers, or other host factors predictive of response to and/or toxicities associated with immune checkpoint inhibitors

AMERICAN BOARD OF PATHOLOGY CONTINUING CERTIFICATION
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Lifelong Learning (Part II) and Self-Assessment Module (SAM) points in the American Board of Pathology’s Maintenance of Certification (MOC) Program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.

If you are interested in having us report ABPath MOC, please ensure the following information is provided within your Member Profile:
- Name - as registered with ABPath
- Date of Birth (Month/Day)
- Your ABPath ID number

Learners must complete the posttest with a passing score of 75% and provide additional documentation following the symposium.

DISCLOSURE OF CONFLICTS OF INTEREST
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

There are no fees required to participate in this activity.

AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.

Food and beverage provided by Clinical Care Options